# Qwen3.8 Max (0902) / mol-d02

Original final answer, shared by both scoring rounds.

All experiments below are **proposed**; no new data are being reported. The recommended next action is a **calibration-first, same-background isogenic protocol** that compares p53-competent, acutely p53-depleted, and near-endogenously rescued cells under a **matched damage load**, using **live-cell fate tracking** plus fixed **DNA-content/nucleotide-incorporation** readouts and explicit **death measurement**. The primary inference should be based on a **death-adjusted, single-cell contrast of damage-induced suppression of S-phase entry**, not on bulk DNA synthesis alone.

---

## 1. Evidence-to-inference-to-conclusion chain

**Evidence from the supplied packet**
1. The historical source summary associates increased p53 with G1 arrest after DNA damage.
2. The same summary states that cells lacking or mutating p53 fail to show the corresponding G1 response.
3. The historical design compared DNA damage, p53 status, G1/G2 changes, and caffeine.
4. The stated limits are:
   - comparisons across different cell lines cannot alone prove same-background causation;
   - pleiotropic drugs cannot alone prove specific causation;
   - reduced DNA synthesis may reflect death or population-composition change rather than true arrest.

**Inferences required for a stronger test**
1. To test **necessity**, p53 must be removed acutely in the same cellular background.
2. To test **specific restoration**, a near-endogenous rescue must restore the arrest phenotype in the depleted background.
3. To avoid confounding by genetic background, all states must be derived from one isogenic parental line.
4. To avoid confounding by toxicity, the damage load must be matched or calibrated.
5. To distinguish true G1 arrest from death or compositional change, cells must be tracked as live individuals and death must be measured independently.
6. To avoid misreading reduced nucleotide incorporation as arrest, DNA-content and nucleotide incorporation must be gated on live cells and interpreted together with live-cell fate.

**Conclusion**
A valid proposed protocol requires:  
**acute p53 depletion + near-endogenous rescue + matched damage + live-cell tracking + fixed DNA-content/nucleotide-incorporation measurement + death measurement + prespecified gating + a quantitative primary contrast.**  
Caffeine should be included only as a **separate perturbation arm**, not as part of the primary causality test.

---

## 2. Core experimental question and hypotheses

### Question
In a single isogenic background, is p53 status **necessary** for damage-induced G1 arrest under the tested damage condition, and is that arrest **specifically restored** by near-endogenous p53 rescue?

### Working definitions
- **Damage-induced G1 arrest**: a reduction in S-phase entry by cells that were alive and in G1 at the time of damage, not explained by cell death or selective loss of other phases.
- **True arrest**: live cells remain viable in G1 and fail to incorporate nucleotide analog, rather than dying or being replaced by a different subpopulation.
- **Matched damage load**: a calibrated damage condition in which the early biological burden is comparable across p53 states, using prespecified live-cell and endpoint criteria.
- **Near-endogenous rescue**: rescue p53 expression tuned to approximate the parental basal and damage-induced p53 level, rather than using uncontrolled overexpression.

### Hypotheses
- **H0, necessity**: acute p53 depletion does not reduce damage-induced G1 arrest.
- **H1, necessity**: acute p53 depletion reduces or abolishes damage-induced G1 arrest.
- **H0, rescue specificity**: rescue does not restore arrest relative to depletion.
- **H1, rescue specificity**: rescue restores arrest toward the p53-competent state.

All hypotheses are condition-specific: they apply only to the selected isogenic background, damage agent, dose, timing, and culture conditions.

---

## 3. Assumptions and unreported parameters

Because the supplied packet does not provide methods-level details, the following are explicitly labeled as **assumptions or parameters to be calibrated**, not as established facts:

1. The parental line is suitable for genetic manipulation and live-cell imaging.
2. A quantitative assay for p53 level or activity is available or must be added before the main experiment.
3. The damage agent and caffeine are available, but their identity, dose, exposure duration, and timing are unknown and must be calibrated.
4. A live-cell method for identifying G1 versus S/G2/M states is available or must be introduced.
5. The exact thresholds for “near-endogenous” rescue, acceptable death, and biologically meaningful arrest must be set during pilot calibration.
6. No historical method is being reconstructed. This is a forward-looking proposed protocol.

---

## 4. Preparation and quality checks

### 4.1 Starting system
Use one isogenic parental line as the common background. The preferred logical states are:

1. **p53-competent parental or parental-like control**
2. **acute p53-depleted derivative**
3. **p53-depleted derivative carrying a near-endogenous rescue**

If the parental line is not p53-functional, then the protocol must instead define a p53-competent restored state and a p53-deficient state within the same background. That situation should be flagged as a constraint before analysis.

### 4.2 Proposed genetic architecture
A robust proposed design is:

- **Acute depletion arm**: endogenous p53 rendered rapidly depletable, for example by an inducible degradation system or another rapid loss-of-function system validated for acute onset.
- **Rescue arm**: a rescue p53 allele that is insensitive to the depletion mechanism and expressed from a controlled locus or tuned expression system.
- **Empty-vector or ligand-only controls** for each background.

The exact molecular implementation is not specified by the evidence packet and should be selected during feasibility assessment.

### 4.3 Clone and background quality control
Before the main experiment, perform:

1. Identity confirmation of the parental background.
2. Verification that engineered derivatives remain in the same background.
3. Exclusion of mycoplasma or other contamination.
4. Baseline growth-rate comparison across states.
5. Baseline cell-cycle distribution comparison across states.
6. Baseline death-rate comparison across states.
7. Verification of p53 status and p53 responsiveness in the competent state.
8. If feasible, assessment of clone-to-clone variability using at least two independent engineered clones or independently derived populations.

### 4.4 p53 validation requirements
Before testing the arrest phenotype, validate:

1. **p53 level in the competent state**
2. **p53 reduction kinetics in the depleted state**
3. **rescue p53 level in the rescued state**
4. **damage-induced p53 elevation**, if measurable, in competent and rescued states

If no reliable p53 measurement is available, the protocol cannot distinguish p53-specific effects from manipulation artifacts. In that case, add a p53 protein or activity assay before proceeding.

---

## 5. Calibration phase

All unknown parameters must be calibrated before the definitive experiment. Calibration is part of the protocol, not an afterthought.

### 5.1 Calibrate acute p53 depletion
Objective: define the shortest depletion interval that produces strong p53 loss while preserving baseline viability.

Procedure:
1. Apply the depletion trigger across a time course.
2. Measure p53 level and cell viability at multiple time points.
3. Select the earliest time point at which p53 is sufficiently reduced and baseline death remains low.
4. Define an acceptable residual p53 threshold and baseline-death ceiling during pilot calibration.

Proposed acceptance concept:
- Depletion is accepted only if it is rapid, strong, and does not by itself cause excessive death or major cell-cycle redistribution before damage.

### 5.2 Calibrate near-endogenous rescue
Objective: tune rescue expression so that it approximates the parental p53 program.

Procedure:
1. Titrate rescue expression over a defined range.
2. Measure basal p53 level and, if possible, damage-induced p53 elevation.
3. Select the rescue level that most closely matches the competent state without causing overt baseline toxicity.
4. Test whether rescue alone alters baseline cell-cycle distribution or death.

Proposed acceptance concept:
- Rescue is considered “near-endogenous” only if basal and induced p53 levels fall within a prespecified acceptable interval around the parental state.
- The exact fold-range is a calibration parameter and should be fixed before the main experiment.

### 5.3 Calibrate live-cell phase classification
Objective: make live-cell G1 assignment reliable enough to define the starting cohort.

Procedure:
1. Introduce or validate a live-cell cycle reporter or live-cell classification scheme.
2. Image untreated cells across at least one full cell cycle.
3. Validate live-phase calls against fixed endpoint DNA-content and nucleotide-incorporation readouts in matched or parallel cultures.
4. Define imaging interval, exposure settings, and phototoxicity limits.

Proposed acceptance concept:
- Live G1 classification must be concordant with endpoint 2N/EdU-negative status at a prespecified level.
- If phase classification cannot be validated, the protocol must pause, because true G1 arrest cannot be assigned reliably.

### 5.4 Calibrate damage agent, dose, and timing
Objective: identify one damage condition that produces measurable G1 arrest in the p53-competent state without excessive death.

Procedure:
1. Treat the p53-competent state with a dilution series of the available damage agent.
2. Measure:
   - live-cell death,
   - cell-cycle distribution,
   - nucleotide incorporation,
   - time to S-phase entry,
   - and, if possible, p53 elevation.
3. Select a candidate damage dose and endpoint time that satisfy:
   - clear damage-induced reduction in S-phase entry in the competent state,
   - acceptable death level,
   - enough live tracked cells for analysis,
   - an endpoint before culture-wide deterioration.

Then test the same candidate in depleted and rescued states.

### 5.5 Match the damage load
Objective: ensure that genotype differences are not caused by different initial damage burden.

Because the packet does not supply an independent lesion marker, matched load must be operationally defined using early live-cell and endpoint readouts.

Proposed matching procedure:
1. Define an early “match-check” time point that occurs before the expected divergence in G1/S behavior.
2. At that time point, compare across states:
   - acute death fraction,
   - gross live-cell morphology,
   - live-cell density or growth trend,
   - DNA-content distribution among live cells,
   - and baseline nucleotide incorporation if appropriate.
3. If the depleted or rescued state differs too much from the competent state, adjust the damage concentration within a prespecified range.
4. Lock the final matched damage condition before the main experiment.

If no condition can produce an acceptable matched load, the protocol should stop or proceed only as an explicitly exploratory mismatched comparison.

### 5.6 Calibrate caffeine as a separate perturbation
Objective: select a caffeine condition that can be analyzed separately without dominating the experiment by toxicity.

Procedure:
1. Test caffeine alone in competent, depleted, and rescued states.
2. Test caffeine together with the calibrated damage condition.
3. Select a caffeine dose and timing that:
   - produces a detectable cell-cycle or checkpoint-related effect,
   - does not cause excessive death by itself,
   - does not make the damage condition uninterpretable.

Caffeine must remain a **separate perturbation arm**. It should not be merged into the primary p53-necessity contrast.

### 5.7 Calibrate nucleotide incorporation and death readouts
Procedure:
1. Titrate nucleotide analog pulse length so that S-phase cells are clearly positive while G1 cells remain negative.
2. Confirm that the pulse does not itself perturb the cell cycle.
3. Calibrate live-death labeling so that dead cells are detected without increasing background toxicity.
4. Define endpoint fixation and staining conditions that preserve DNA-content resolution.

---

## 6. Main experimental design

### 6.1 Factorial structure
The main experiment should include, at minimum, the following no-caffeine conditions:

| State | Vehicle | Damage |
|---|---:|---:|
| p53-competent | yes | yes |
| acute p53-depleted | yes | yes |
| rescued | yes | yes |

In addition, include caffeine as a separate parallel matrix:

| State | Caffeine only | Damage + caffeine |
|---|---:|---:|
| p53-competent | yes | yes |
| acute p53-depleted | yes | yes |
| rescued | yes | yes |

Also include all relevant inducer, ligand, vector, and vehicle controls required by the depletion/rescue system.

### 6.2 Independent experimental units
- The independent unit should be an independently prepared culture or well, not multiple fields from the same well.
- Technical replicates within the same culture may be used for precision but must not be treated as independent biological replicates.
- If multiple engineered clones are used, clone should be included as a blocking or random factor.

### 6.3 Allocation and blinding
1. Randomize plate layout and imaging fields across conditions.
2. Randomize the order of treatment and acquisition where feasible.
3. Code samples so that genotype and treatment are masked during:
   - gating,
   - tracking curation,
   - fate scoring,
   - and primary analysis.
4. Reveal codes only after quality-control and exclusion rules have been applied.

### 6.4 Sampling timeline
A proposed timeline is:

1. Seed cells at standardized density.
2. Begin baseline live-cell imaging.
3. Apply depletion trigger or control according to calibration.
4. Apply caffeine or caffeine vehicle where assigned.
5. Apply damage agent or damage vehicle at the calibrated matched dose.
6. Continue live-cell imaging through the calibrated endpoint.
7. Apply nucleotide analog pulse near the endpoint.
8. Harvest fixed samples for DNA-content and incorporation readouts.
9. Optionally harvest an early fixed sample at the match-check time point.

The exact timing is a calibration parameter.

---

## 7. Measurements

### 7.1 Live-cell tracking
Track individual cells from before treatment through the endpoint.

For each tracked cell, record:
- state identity,
- treatment,
- phase at treatment time,
- time of S-phase entry if it occurs,
- time of death if it occurs,
- time of division if it occurs,
- final fate at endpoint,
- and any censored loss from the field.

The primary live-cell cohort should be cells that are **alive and classified as G1 at the time of damage**. This directly tests G1 arrest and avoids composition artifacts arising from later-phase selective loss.

### 7.2 Fixed DNA-content measurement
At the endpoint, measure DNA content in fixed cells to identify:
- G1/2N population,
- S-phase intermediate population,
- G2/M/4N population,
- sub-G1 or debris fraction where relevant.

This measurement must be performed on live-gated or viability-corrected events wherever possible.

### 7.3 Fixed nucleotide-incorporation measurement
Measure nucleotide analog incorporation at the single-cell level.

This allows classification of:
- live G1 cells that are incorporation-negative,
- live S cells that are incorporation-positive,
- and live G2/M cells with the appropriate incorporation profile.

This readout is essential because DNA content alone cannot distinguish quiescent/arrested G1 from simply having many G1 cells for compositional reasons.

### 7.4 Death measurement
Measure death in two complementary ways:
1. live-cell death classification during tracking;
2. endpoint live/dead or death-marker measurement before fixation or before cell-cycle gating.

Death must be reported as:
- cumulative death by endpoint,
- death before S-phase entry,
- and death in each genotype/treatment state.

---

## 8. Prespecified gating and fate rules

All gates and fate rules must be fixed before unblinding.

### 8.1 Fixed cytometry or imaging gates
Use the following hierarchical gates:

1. **Acquisition quality gate**  
   Exclude clogged, undercounted, or technically failed samples.

2. **Single-cell gate**  
   Exclude doublets or segmented aggregates.

3. **Live/dead gate**  
   Quantify dead cells and exclude them from live cell-cycle fractions.

4. **DNA-content gates**  
   Define:
   - G1/2N,
   - S,
   - G2/M.

5. **Nucleotide-incorporation gate**  
   Define incorporation-positive and incorporation-negative populations using:
   - no-analog controls,
   - known S-phase population,
   - and consistent thresholding across all samples.

6. **Combined phase/incorporation gates**  
   Define at minimum:
   - live G1 incorporation-negative,
   - live S incorporation-positive,
   - live G2/M incorporation-low/negative as appropriate.

### 8.2 Live-cell fate gates
For the primary cohort of live G1 cells at treatment, assign one mutually exclusive fate by endpoint:

1. **Arrested G1**  
   Alive at endpoint, no S entry observed, incorporation-negative if endpoint correlation is available.

2. **Entered S**  
   Reached S phase before endpoint and remained alive at least until entry.

3. **Died before S entry**  
   Death observed before any S-phase entry.

4. **Died after S entry**  
   Death occurred after S entry; not counted as G1 arrest.

5. **Divided**  
   Completed division before endpoint.

6. **Censored/lost**  
   Lost due to tracking failure, migration out of field, or segmentation failure.

### 8.3 Distinguishing arrest from death or composition
The design distinguishes these possibilities as follows:

- **True arrest** is supported when:
  - live G1 cells remain alive,
  - they fail to enter S,
  - they are incorporation-negative,
  - death is low or at least not responsible for the missing S-phase cells.

- **Death-driven apparent arrest** is suspected when:
  - S-entry reduction is accompanied by high pre-S death,
  - dead cells accumulate in the would-be arrested gate,
  - or live-cell tracking shows disappearance before S entry.

- **Composition-driven apparent arrest** is suspected when:
  - the G1 fraction increases because other phases are selectively lost,
  - baseline phase distribution differs strongly,
  - or live tracking shows selective death of S/G2 cells rather than persistent G1 cells.

This is why the primary analysis should condition on the starting live G1 cohort rather than relying only on endpoint population fractions.

---

## 9. Quantitative primary contrast

### 9.1 Primary estimand
Define, for each genotype state \(g\):

- \(P_{S,g,V}\) = probability of S-phase entry by the endpoint among cells alive and in G1 at treatment time in the **vehicle** condition.
- \(P_{S,g,D}\) = probability of S-phase entry by the endpoint among cells alive and in G1 at treatment time in the **damage** condition.

Because death can prevent S entry, estimate these as **death-adjusted probabilities**, for example using a competing-risk framework where:
- S entry is the event of interest,
- death before S entry is a competing event.

Define the damage-induced arrest index:

\[
A_g = P_{S,g,V} - P_{S,g,D}
\]

A positive \(A_g\) means damage reduces S-phase entry, consistent with arrest.

### 9.2 Primary contrast
The proposed primary contrast is the rescue restoration contrast:

\[
\Delta_{\text{primary}} = A_{\text{rescue}} - A_{\text{depleted}}
\]

Interpretation:
- \(\Delta_{\text{primary}} > 0\): rescue restores damage-induced suppression of S entry relative to depletion.
- \(\Delta_{\text{primary}} \approx 0\): rescue does not restore arrest.
- \(\Delta_{\text{primary}} < 0\): rescue worsens the arrest metric, suggesting toxicity, misexpression, or model failure.

### 9.3 Prespecified necessity gate
Because the scientific question also includes necessity, add a prespecified assay-sensitivity gate:

\[
\Delta_{\text{necessity}} = A_{\text{competent}} - A_{\text{depleted}}
\]

The protocol should require:

\[
\Delta_{\text{necessity}} > \delta_{\text{gate}}
\]

where \(\delta_{\text{gate}}\) is a prespecified minimum biologically meaningful effect set during pilot calibration.

If this gate is not met, the selected damage condition cannot support a claim that p53 is necessary, even if rescue behaves differently.

### 9.4 Rescue-specificity gate
To test whether rescue specifically restores the competent phenotype, define:

\[
\Delta_{\text{specificity}} = A_{\text{rescue}} - A_{\text{competent}}
\]

Prespecified success can be defined as:

\[
|\Delta_{\text{specificity}}| \leq \varepsilon
\]

where \(\varepsilon\) is an equivalence margin chosen during calibration.

Thus, the full conclusion requires:
1. a positive primary rescue contrast,
2. a positive necessity gate,
3. rescue within the acceptable equivalence range of the competent state,
4. and death/composition checks that do not invalidate the arrest interpretation.

### 9.5 Secondary supporting contrasts
Use the fixed endpoint data as supporting evidence:

1. **Live G1 incorporation-negative fraction**  
   Compare damage versus vehicle within each state.

2. **Live S-phase fraction**  
   Compare damage-induced suppression of S across states.

3. **Death fraction**  
   Compare death across states to rule out death-driven artifacts.

4. **Caffeine response profile**  
   Compare no-caffeine and caffeine arms separately by state.

These are supportive, not primary, because the live-cell death-adjusted contrast is the most direct test.

### 9.6 Statistical analysis plan
A suitable proposed analysis is:

1. Estimate \(P_S\) and \(A_g\) per independent replicate.
2. Use a mixed-effects model or competing-risk regression with:
   - genotype state,
   - damage condition,
   - caffeine status in separate secondary analyses,
   - batch or experiment as random effects,
   - and clone as a factor if multiple clones are used.
3. Report:
   - point estimates,
   - confidence or credible intervals,
   - and prespecified decision thresholds.
4. Do not treat technical fields or multiple cells from the same culture as independent observations.

---

## 10. Controls and interpretation logic

### 10.1 Controls required
The protocol should include:

1. vehicle-only controls for damage and caffeine;
2. depletion-trigger controls in competent cells;
3. rescue-only controls to detect expression artifacts;
4. empty-vector or construct controls where applicable;
5. baseline proliferation and death controls;
6. positive arrest reference in the competent damaged state;
7. early match-check samples for damage-load comparison.

### 10.2 Interpretation matrix

| Outcome | Interpretation |
|---|---|
| Competent damaged cells arrest; depleted cells do not; rescue restores arrest | Supports p53 necessity and specific rescue under tested condition |
| Competent and depleted cells both arrest | p53 not necessary under tested condition |
| Depleted cells arrest but rescue fails to restore | Rescue insufficient, misexpressed, or non-specific |
| Rescue restores arrest but competent state does not | System invalid or rescue artifact; do not infer necessity |
| Apparent arrest loss accompanied by high death | Interpretation compromised; death must be modeled explicitly |
| Apparent arrest explained by selective loss of other phases | Composition artifact; true arrest not established |

### 10.3 Caffeine interpretation
Caffeine arms are analyzed separately.

Possible uses:
- to test whether the arrest phenotype can be modified by a pharmacological perturbation;
- to probe whether damage-response timing or checkpoint strength differs by state;
- to identify pleiotropic toxicity if caffeine alone alters death or cycle distribution.

Caffeine should not be used to prove p53 necessity. It is a separate perturbation whose mechanism may be pleiotropic.

---

## 11. Acceptance and stopping criteria

These criteria must be set before the main experiment.

### 11.1 Calibration acceptance criteria
Proceed only if:

1. p53 depletion is acute and sufficiently strong;
2. rescue expression is within the prespecified near-endogenous range;
3. live G1 classification is validated;
4. damage produces a measurable G1 arrest in the competent state;
5. death in the primary condition remains below the prespecified ceiling;
6. matched-load criteria are satisfied or explicitly documented as unsatisfied;
7. caffeine alone does not cause unacceptable toxicity.

### 11.2 Main-experiment acceptance criteria
A definitive run is acceptable only if:

1. enough live tracked G1 cells are available per condition;
2. vehicle controls are stable;
3. death in vehicle controls is low;
4. imaging quality permits unambiguous fate assignment;
5. fixed DNA-content and incorporation gates are clean and reproducible;
6. blinding and randomization were maintained.

The minimum number of tracked cells should be determined from pilot variance. If no pilot estimate exists, use a provisional minimum and state it explicitly as an assumption.

### 11.3 Stopping rules
Stop or recalibrate if:

1. the competent state does not show damage-induced arrest after calibration;
2. depletion is incomplete or too slow;
3. rescue expression is far above or below the target range;
4. death is too high in any primary condition;
5. matched damage load cannot be achieved;
6. live G1 classification fails validation;
7. caffeine alone causes excessive toxicity.

If stopping rules are triggered, the correct response is not to reinterpret the endpoint post hoc, but to recalibrate the system or acknowledge that the hypothesis cannot be tested under the chosen conditions.

---

## 12. Troubleshooting

### Problem: No G1 arrest in competent damaged cells
Possible actions:
- increase damage dose within the calibrated range;
- move the endpoint earlier or later;
- verify p53 functionality and damage-induced elevation;
- confirm that the selected damage agent can produce a G1 response in this background;
- if no condition works, stop and report that the condition is not testable.

### Problem: Apparent arrest but high death
Possible actions:
- lower damage dose;
- shorten exposure;
- reduce caffeine dose if present;
- switch to death-adjusted competing-risk analysis;
- if death remains high, do not claim true arrest.

### Problem: Rescue expression too high
Possible actions:
- reduce expression level;
- select a lower-expressing clone;
- use a weaker induction condition;
- re-evaluate after re-titration.

### Problem: Rescue expression too low
Possible actions:
- increase expression modestly;
- verify rescue transcript/protein stability;
- test another rescue clone;
- if near-endogenous matching cannot be achieved, limit conclusions to exploratory rescue effects.

### Problem: Composition changes dominate endpoint DNA-content data
Possible actions:
- rely more heavily on live-cell conditional analysis;
- add earlier time points;
- compare baseline phase distributions;
- report composition-adjusted secondary metrics;
- avoid interpreting total DNA synthesis alone.

### Problem: Caffeine causes broad toxicity
Possible actions:
- reduce dose;
- shorten exposure;
- move caffeine addition to a different time point;
- exclude caffeine from primary interpretation and report as failed perturbation.

---

## 13. Alternatives and limitations

### 13.1 Alternative depletion strategies
If an acute degradation system is not feasible, alternatives include:
- rapid conditional knockout,
- acute transcriptional repression,
- inducible RNA-mediated depletion.

However, slower systems weaken the claim of acute necessity and increase the risk of adaptive rewiring.

### 13.2 Alternative rescue strategies
If near-endogenous expression is difficult:
- use multiple rescue expression levels and model the dose-response;
- report rescue as qualitative rescue only if expression is not well matched;
- avoid claiming specificity unless rescue is within the prespecified expression range.

### 13.3 If live-cell cycle classification is unavailable
The protocol can fall back on fixed DNA-content and incorporation endpoints, but the ability to distinguish true G1 arrest from composition change will be substantially weaker. In that case, conclusions should be downgraded from causal to correlative.

### 13.4 Limits of the matched-load solution
Because the packet does not provide a direct lesion marker, matched damage load is inferred from early viability and live-cell behavior. This is an operational approximation, not a perfect measurement. If p53 status changes damage repair or survival before the first G1/S decision, residual mismatch may remain.

### 13.5 Limits of caffeine
Caffeine is pleiotropic. It can modify cell-cycle behavior without being specific to p53. Therefore, caffeine results should be interpreted only as separate perturbation evidence, not as proof of p53 mechanism.

### 13.6 Generalization limit
Even if successful, the result applies only to:
- the chosen parental background,
- the selected damage agent,
- the calibrated dose and timing,
- the chosen caffeine condition,
- and the implemented depletion/rescue system.

It does not prove that p53 is universally necessary for all damage-induced G1 arrest programs.

---

## 14. Final recommended protocol summary

1. Build or obtain three same-background states: p53-competent, acutely p53-depleted, and near-endogenously rescued.
2. Validate p53 status, depletion kinetics, and rescue level.
3. Calibrate damage dose and endpoint so that competent cells show arrest with acceptable death.
4. Calibrate caffeine separately.
5. Define a matched damage load using early live-cell and endpoint criteria.
6. Randomize, blind, and run the main experiment with live-cell tracking.
7. At endpoint, measure DNA content and nucleotide incorporation in fixed samples.
8. Measure death in both live and endpoint readouts.
9. Gate live single cells, then classify G1/S/G2/M and incorporation status.
10. Track only cells alive and in G1 at treatment for the primary fate analysis.
11. Estimate death-adjusted S-entry probabilities.
12. Compute the primary rescue contrast:
   \[
   \Delta_{\text{primary}} = A_{\text{rescue}} - A_{\text{depleted}}
   \]
13. Require a positive necessity gate:
   \[
   \Delta_{\text{necessity}} = A_{\text{competent}} - A_{\text{depleted}}
   \]
14. Require rescue specificity:
   \[
   |A_{\text{rescue}} - A_{\text{competent}}| \leq \varepsilon
   \]
15. Interpret only if death and composition checks do not explain the result.

If these prespecified conditions are met, the protocol provides a strong same-background test that p53 is necessary for damage-induced G1 arrest under the tested damage condition and that the arrest defect is specifically restored by near-endogenous rescue. If they are not met, the correct conclusion is that the evidence is insufficient under the tested conditions, not that p53 is or is not necessary in general.
